Drugs / Bimekizumab
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Bimzelx | — | 2021-08-20 | europa.eu ↗ |
Trials 51 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT07290036 | Dec 2025 → May 2028 expected | psoriatic arthritis, spondyloarthropathy | UCB Biopharma SRL | Recruiting | No outcome recorded |
| Phase 1 | NCT06888193 | Nov 2025 → May 2027 expected | hidradenitis suppurativa, psoriasis, psoriatic arthritis, spondyloarthropathy | UCB Biopharma SRL | Recruiting | No outcome recorded |
| Phase 1 | NCT03895385 | Apr → Oct 2019 | — | UCB Biopharma S.P.R.L. | Completed | No outcome recorded |
| Phase 1 | NCT03707717 | Oct 2018 → Jun 2019 | — | UCB Biopharma S.P.R.L. | Completed | No outcome recorded |
| Phase 1 | NCT05028127 | Mar → Jun 2016 | — | UCB Celltech | Completed | No outcome recorded |
| Phase 1 | NCT02141763 | May 2014 → Aug 2015 | psoriatic arthritis | UCB Celltech | Completed | No outcome recorded |
| Phase 1 | NCT02529956 | Nov 2012 → Jan 2014 | psoriasis | UCB Celltech | Completed | No outcome recorded |
| Phase 214 trials | ||||||
| Phase 2 | NCT07138898 | Dec 2025 → Jan 2028 expected | rheumatic disorder | NYU Langone Health | Recruiting | No outcome recorded |
| Phase 2 | NCT06742333 | Jul 2025 → Jul 2028 expected | psoriasis | Centre Hospitalier Universitaire de Nice | Recruiting | No outcome recorded |
| Phase 2 | NCT04718896 | Apr 2021 → Mar 2025 | psoriasis | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 2 | NCT03355573 | Nov 2017 → Oct 2022 | ankylosing spondylitis | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 2 | NCT03347110 | Nov 2017 → Oct 2020 | psoriatic arthritis | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 2 | NCT03215277 | Oct 2017 → May 2020 | ankylosing spondylitis | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 2 | NCT03248531 | Sep 2017 → Nov 2018 | hidradenitis suppurativa | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 2 | NCT03230292 | Jul 2017 → Mar 2019 | psoriasis | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 2 | NCT03025542 | Dec 2016 → Dec 2017 | psoriasis | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 2 | NCT03010527 | Dec 2016 → Sep 2018 | psoriasis | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 2 | NCT02969525 | Oct 2016 → Nov 2017 | psoriatic arthritis | UCB Biopharma S.P.R.L. | Completed | No outcome recorded |
| Phase 2 | NCT02963506 | Oct 2016 → Oct 2017 | ankylosing spondylitis | UCB Biopharma S.P.R.L. | Completed | No outcome recorded |
| Phase 2 | NCT02905006 | Aug 2016 → Jun 2017 | psoriasis | UCB Biopharma S.P.R.L. | Completed | No outcome recorded |
| Phase 2 | NCT02430909 | Apr 2015 → Apr 2017 | rheumatoid arthritis | UCB Celltech | Completed | No outcome recorded |
| Phase 323 trials | ||||||
| Phase 3 | NCT07219420 | Nov 2025 → Dec 2027 expected | palmoplantar pustulosis | UCB Biopharma SRL | Recruiting | No outcome recorded |
| Phase 3 | NCT06921850 | Apr 2025 → Dec 2026 expected | hidradenitis suppurativa | UCB Biopharma SRL | Recruiting | No outcome recorded |
| Phase 3 | NCT06668181 | Mar 2025 → Apr 2028 expected | enthesitis-related juvenile idiopathic arthritis, psoriasis-related juvenile idiopathic arthritis | UCB Biopharma SRL | Recruiting | No outcome recorded |
| Phase 3 | NCT06624228 | Oct 2024 → Feb 2026 | psoriatic arthritis | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 3 | NCT06506916 | Jul 2024 → Mar 2027 expected | psoriasis, psoriatic arthritis | UCB Biopharma SRL | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06425549 | Jun 2024 → Aug 2028 expected | psoriasis | UCB Biopharma SRL | Recruiting | No outcome recorded |
| Phase 3 | NCT06011733 | Oct 2023 → Feb 2025 | psoriasis | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 3 | NCT05020249 | Sep 2021 → Sep 2022 | psoriasis | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 3 | NCT04901195 | May 2021 → Jul 2026 overdue | hidradenitis suppurativa | UCB Biopharma SRL | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04436640 | Jun 2020 → Aug 2026 overdue | ankylosing spondylitis | UCB Biopharma SRL | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04242498 | Mar 2020 → Nov 2021 | hidradenitis suppurativa | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 3 | NCT04242446 | Feb 2020 → Apr 2022 | hidradenitis suppurativa | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 3 | NCT04009499 | Aug 2019 → May 2026 | psoriatic arthritis | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 3 | NCT03928743 | Apr 2019 → Sep 2021 | ankylosing spondylitis | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 3 | NCT03928704 | Apr 2019 → Jun 2022 | spondyloarthropathy | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 3 | NCT03895203 | Apr 2019 → Aug 2021 | psoriatic arthritis | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 3 | NCT03896581 | Mar 2019 → Dec 2021 | psoriatic arthritis | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 3 | NCT03766685 | Dec 2018 → Jul 2020 | psoriasis | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 3 | NCT03598790 | Sep 2018 → Nov 2023 | psoriasis | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 3 | NCT03536884 | Jun 2018 → Sep 2019 | psoriasis | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 3 | NCT03410992 | Feb → Dec 2018 | psoriasis, psoriatic arthritis | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 3 | NCT03412747 | Jan 2018 → Feb 2019 | psoriasis | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 3 | NCT03370133 | Dec 2017 → Jan 2019 | psoriasis, psoriatic arthritis | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 47 trials | ||||||
| Phase 4 | NCT07352566 | Aug 2026 → Jun 2030 expected | atopic eczema, psoriasis | University of California, San Francisco | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07497620 | Jul 2026 → Aug 2027 expected | adult onset pityriasis rubra pilaris | Mayo Clinic | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07554014 | Apr 2026 → Sep 2027 expected | hidradenitis suppurativa | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07149792 | Jul 2025 → Dec 2026 expected | psoriasis, psoriatic arthritis | Taichung Veterans General Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06336343 | Jun 2024 → Mar 2026 | psoriasis | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 4 | NCT05499416 | Jan → Sep 2023 | psoriasis, psoriatic arthritis | Innovaderm Research Inc. | Withdrawn | No outcome recorded |
| Phase 4 | NCT04340076 | Aug 2020 → Jan 2025 | psoriasis | Radboud University Medical Center | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04109976 Background | Aug 2019 → Nov 2020 | psoriatic arthritis | UCB Biopharma SRL | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 58 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bimekizumab | “bimekizumab, a humanised monoclonal IgG1 antibody” PMID 29275332 ↗ Dec 201751“Bimekizumab 120 mg + NAFL (1565 nm)” NCT07554014 ↗ “bimekizumab (formerly UCB4940)” PMID 27859546 ↗ Jan 2017 “Bimekizumab (Bimzelx)” NCT07149792 ↗ |
| Known as | Bimekizumab-bkzx | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297700 ↗ |
| Known as | Bimzelx | “Bimekizumab (Bimzelx)” NCT07149792 ↗ |
| Known as | BKZ | “Bimekizumab (BKZ), an IL-17A and IL-17F inhibitor, has demonstrated a rapid and high level of complete skin clearance in patients with psoriasis and complete normalization of...” PMID 41580158 ↗ Jan 20262“OBJECTIVE: To assess the long-term safety profile of bimekizumab (BKZ) in patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA).” PMID 40194794 ↗ Apr 2025 “Participants will receive bimekizumab (BKZ) at pre-specified time points.” NCT07290036 ↗ |
| Known as | UCB4940 | “The purpose of this study is to evaluate the safety, efficacy and body distribution of Bimekizumab (UCB4940) when added to Certolizumab Pegol treatment in patients with...” NCT02430909 ↗ |
| Action | Inhibit | “Neutralisation of IL-17A and IL-17F with bimekizumab” PMID 29275332 ↗ Dec 2017 |
| Modality | Monoclonal antibody | “bimekizumab, a humanised monoclonal IgG1 antibody” PMID 29275332 ↗ Dec 2017 |
| Route | Intravenous | “Route of Administration: intravenous” NCT02141763 ↗ |
| Target | IL17A | “a monoclonal antibody that selectively neutralises IL17A and IL17F” PMID 32035552 ↗ Feb 2020 |
| Target | IL17F | “a monoclonal antibody that selectively neutralises IL17A and IL17F” PMID 32035552 ↗ Feb 2020 |